Information Provided By:
Fly News Breaks for July 23, 2019
VIVE
Jul 23, 2019 | 07:16 EDT
Mizuho analyst Difei Yang double downgraded Viveve Medical to Underperform from Buy and cut her price target for the shares to 20c from $4.00. The analyst cites the failed Liberate trial and the company's restructuring for the downgrade.
News For VIVE From the Last 2 Days
There are no results for your query VIVE